The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial
Abstract
PURPOSE: We conducted this randomized study comparing the activity and toxicity of paclitaxel and gemcitabine (PG) and paclitaxel and carboplatin (PC) combinations for the treatment of advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Chemotherapy-naive patients were randomized to paclitaxel 200 mg/m 2 on day 1 plus either carboplatin at an area under the concentration-time curve of 6 on day 1 (group A) or gemcitabine 1,000 mg/m 2 on days 1 and 8 (group B) every 3 weeks. A retrospective cost analysis was conducted using Student’s t test to compare independent samples between groups. RESULTS: A total of 509 patients (group A, 252 patients; group B, 257 patients) were enrolled; all characteristics were well balanced. The median survival time was 10.4 months (95% confidence interval [CI], 8.8 to 12 months) for group A and 9.8 months (95% CI, 8.0 to 11.7 months) for group B (P = .32). Respective 1-year survival rates were 41.7% and 41.4%. The response rate for group A was 28.0% (2% complete response [CR], 26% partial response [PR] [95% CI, 22% to 34%]), and the response rate for group B was 35.0% (5% CR, 30% PR) [95% CI, 29% to 41%]) (P = .12). Toxicity was mild. Grades 3/4 neutropenia, thrombocytopenia, and anemia for groups A and B were seen in 15% and 15%, 2% and 1%, and 5% and 2%, respectively. The mean total cost (outpatient clinic visits plus chemotherapy drug fee) for group A (€ 7,612.64) versus group B (€ 7,484.77) was not statistically significant (P < .66). CONCLUSION: The PG combination is as equally active and well tolerated as the PC combination in patients with advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Cullen, M. H., Billingham, L. J., Woodroffe, C. M., Chetiyawardana, A. D., Gower, N. H., Joshi, R., Ferry, D. R., Rudd, R. M., Spiro, S. G., Cook, J. E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3188 · Cited by 445
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.384 · Cited by 429
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Georgoulias, V, Papadakis, E., Alexopoulos, A., Tsiafaki, X., Rapti, A., Veslemes, M., Palamidas, P., & Vlachonikolis, I. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04644-4 · Cited by 346
Bonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C., Blum, R. H., Green, M. D., Mason, B., Hahn, R., Tormey, D. C., Harris, J., & Comis, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1602 · Cited by 323
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.297 · Cited by 303
Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., & Ozols, R. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1860 · Cited by 295
Gatzemeier, U., Shepherd, F. A., Le Chevalier, T., Weynants, P., Cottier, B., Groen, H. J. M., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00444-0 · Cited by 241
Rowinsky, E. K., Chaudhry, V, Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., & Donehower, R. C. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.2010 · Cited by 192
Abratt, R. P., Bezwoda, W. R., Goedhals, L., & Hacking, D. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.744 · Cited by 177
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
Hainsworth, J. D., Thompson, D. S., & Greco, F. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1609 · Cited by 160
Kroep, J. R., Giaccone, G., Voorn, D. A., Smit, E. F., Beijnen, J. H., Rosing, H., van Moorsel, C. J. A., van Groeningen, C. J., Postmus, P. E., Pinedo, H. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2190 · Cited by 144
Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
Johnson, D. H., Paul, D., Hande, K. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2054 · Cited by 134
Gemcitabine: A pharmacologic and clinical overview
Barton‐Burke, M. (1999) · Cancer Nursing · doi:10.1097/00002820-199904000-00011 · Cited by 130
Taxol: Twenty Years Later, the Story Unfolds
Rowinsky, E. K., & Donehower, R. C. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1778 · Cited by 89
A phase I–II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
Giaccone, G., Smit, E. F., van Meerbeeck, J. P., Splinter, T. A. W., Golding, R. P., Pinedo, H. M., Laan, D., van Tinteren, H., & Postmus, P. E. (2000) · Annals of Oncology · doi:10.1023/a:1008321000887 · Cited by 51
Shepherd, F. A. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199512006-00004 · Cited by 44
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
Kosmidis, P., Mylonakis, N., Fountzilas, G., Samantas, E., Athanasiadis, A., Andreopoulou, E., Pavlidis, N., & Skarlos, D.-V. (1997) · Annals of Oncology · doi:10.1023/a:1008268911935 · Cited by 33
Self-citationChemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier, U., Heckmayer, M., Neuhauss, R., Schlüter, I., von Pawel, J., Wagner, H., & Dreps, A. (1995) · PubMed · Cited by 28
Cited by
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Multidisciplinary Management of Lung Cancer
Spira, A., & Ettinger, D. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035536 · Cited by 922
Role of gemcitabine in cancer therapy
Toschi, L., Finocchiaro, G., Bartolini, S., Gioia, V, & Cappuzzo, F. (2005) · Future Oncology · doi:10.1517/14796694.1.1.7 · Cited by 373
D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.045 · Cited by 363
Smit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351
Metadata
- Authors
- Kosmidis, P., Mylonakis, N., Nicolaides, C., Kalophonos, C., Samantas, E., Boukovinas, J., Fountzilas, G., Skarlos, D., Economopoulos, T., Tsavdaridis, D., Papakostas, P., Bacoyiannis, C., & Dimopoulos, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-09-01
- Volume
- 20
- Issue
- 17
- Pages
- 3578-3585
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155236705
- Cited by
- 255
- References
- 27
- FWCI
- 25.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.